Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A PILOT First-In-Man Study to Evaluate Safety and Efficacy of the EXCEL With Cobalt Chromium Alloys Sirolimus Eluting Biodegradable Polymer Stent in the Treatment of Patients With de Novo Coronary Artery Lesions (CREDIT-I)

Trial Profile

A PILOT First-In-Man Study to Evaluate Safety and Efficacy of the EXCEL With Cobalt Chromium Alloys Sirolimus Eluting Biodegradable Polymer Stent in the Treatment of Patients With de Novo Coronary Artery Lesions (CREDIT-I)

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sirolimus (Primary)
  • Indications Coronary artery disease; Myocardial infarction; Thrombosis; Venous thromboembolism
  • Focus First in man; Therapeutic Use
  • Acronyms CREDIT-I
  • Most Recent Events

    • 11 Mar 2015 Results published in a Biosensors International Group media release.
    • 11 Mar 2015 Status changed from recruiting to active, no longer recruiting, as reported in a Biosensors International Group media release.
    • 05 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top